Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 263

1.

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.

Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022. No abstract available.

PMID:
29348030
2.

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2018 Jan 8. pii: dc171778. doi: 10.2337/dc17-1778. [Epub ahead of print]

PMID:
29311155
3.

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM.

Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.

PMID:
29203583
4.

Biomarkers of tubulointerstitial damage and function in type 1 diabetes.

de Boer IH, Gao X, Bebu I, Hoofnagle AN, Lachin JM, Paterson A, Perkins BA, Saenger AK, Steffes MW, Zinman B, Molitch ME.

BMJ Open Diabetes Res Care. 2017 Nov 14;5(1):e000461. doi: 10.1136/bmjdrc-2017-000461. eCollection 2017.

5.

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD; DCCT/EDIC Research Group.

Diabetes Care. 2017 Dec;40(12):1756-1762. doi: 10.2337/dc16-2523.

PMID:
29138273
6.

Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777-783.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Nov;40(11):e165-e166. doi: 10.2337/dci17-0038. No abstract available.

PMID:
29061594
7.

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511.

PMID:
29020355
8.

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.

Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6.

PMID:
28986504
9.

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators.

Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.

PMID:
28904068
10.

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.

Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group.

Hypertension. 2017 Nov;70(5):907-914. doi: 10.1161/HYPERTENSIONAHA.117.09482. Epub 2017 Aug 28.

PMID:
28847886
11.

The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study.

Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, Nathan DM, Lachin JM; DCCT/EDIC Research Group.

Diabetologia. 2017 Oct;60(10):2084-2091. doi: 10.1007/s00125-017-4374-4. Epub 2017 Jul 16.

PMID:
28711972
12.

Frequency of Evidence-Based Screening for Diabetic Retinopathy.

Nathan DM, Bebu I, Lachin JM.

N Engl J Med. 2017 Jul 13;377(2):195. doi: 10.1056/NEJMc1706322. No abstract available.

PMID:
28700836
13.

Refining Measurement of Hemoglobin A1c.

Sacks DB, Bebu I, Lachin JM.

Clin Chem. 2017 Sep;63(9):1433-1435. doi: 10.1373/clinchem.2016.268573. Epub 2017 Jun 20. No abstract available.

PMID:
28634223
14.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

15.

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.

Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

Diabetes Care. 2017 Aug;40(8):1010-1016. doi: 10.2337/dc16-2723. Epub 2017 May 26.

PMID:
28550194
16.

Optimal screening schedules for disease progression with application to diabetic retinopathy.

Bebu I, Lachin JM.

Biostatistics. 2018 Jan 1;19(1):1-13. doi: 10.1093/biostatistics/kxx009.

PMID:
28430872
17.

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM.

N Engl J Med. 2017 Apr 20;376(16):1507-1516. doi: 10.1056/NEJMoa1612836.

18.

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Jun;40(6):777-783. doi: 10.2337/dc16-2426. Epub 2017 Apr 12.

PMID:
28404658
19.

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.

20.

Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.

Guglielmi C, Del Toro R, Lauria A, Maurizi AR, Fallucca S, Cappelli A, Angeletti S, Lachin JM, Pozzilli P.

Diabetes Metab Res Rev. 2017 Sep;33(6). doi: 10.1002/dmrr.2899. Epub 2017 May 9.

PMID:
28371189

Supplemental Content

Loading ...
Support Center